These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 9678917

  • 1. Politics could hamper FDA reform.
    Fox JL.
    Biotechnology (N Y); 1995 Nov; 13(11):1156. PubMed ID: 9678917
    [No Abstract] [Full Text] [Related]

  • 2. FDA performance goals for approving drugs and biologics.
    Miller JD.
    JAMA; 2009 Jul 08; 302(2):189-91. PubMed ID: 19584348
    [No Abstract] [Full Text] [Related]

  • 3. Will politics sidetrack FDA reform?
    Gatty B.
    Formulary; 1995 Aug 08; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract] [Full Text] [Related]

  • 4. FDA "reform"?
    Feinstone SM, Lewis AM, Markoff LJ, Carbone K, Golding H.
    Science; 1998 Jan 09; 279(5348):157-8. PubMed ID: 9446214
    [No Abstract] [Full Text] [Related]

  • 5. FDA centennial.
    Kennedy D.
    Science; 2006 Apr 07; 312(5770):19. PubMed ID: 16601155
    [No Abstract] [Full Text] [Related]

  • 6. The FDA is no place for politics.
    Nat Struct Mol Biol; 2006 May 07; 13(5):379. PubMed ID: 16738601
    [No Abstract] [Full Text] [Related]

  • 7. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M.
    N Engl J Med; 2007 Apr 26; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract] [Full Text] [Related]

  • 8. Regulator under siege.
    Wadman M.
    Nature; 2007 Dec 20; 450(7173):1143. PubMed ID: 18097370
    [No Abstract] [Full Text] [Related]

  • 9. What ails the FDA?
    Marcus DM.
    N Engl J Med; 2005 Jun 16; 352(24):2554. PubMed ID: 15962405
    [No Abstract] [Full Text] [Related]

  • 10. Confronting the future of the FDA.
    Serafini MW.
    Natl J (Wash); 1996 Dec 14; 28(50):2704-5. PubMed ID: 10163877
    [No Abstract] [Full Text] [Related]

  • 11. FDA reforms hampered by budget freeze.
    Jaffe S.
    Lancet; 2012 Oct 27; 380(9852):1458-9. PubMed ID: 23115783
    [No Abstract] [Full Text] [Related]

  • 12. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P.
    MedGenMed; 2006 Oct 30; 8(4):22. PubMed ID: 17415305
    [No Abstract] [Full Text] [Related]

  • 13. Cash infusion. White House seeks to boost oversight at FDA.
    Conn J.
    Mod Healthc; 2008 Jun 16; 38(24):8-9. PubMed ID: 18661618
    [No Abstract] [Full Text] [Related]

  • 14. The big gap at the FDA.
    Stipp D.
    Fortune; 2002 Jul 22; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract] [Full Text] [Related]

  • 15. The politics of FDA reform.
    Bérubé JE.
    J Head Trauma Rehabil; 1998 Apr 22; 13(2):78-85. PubMed ID: 9575259
    [No Abstract] [Full Text] [Related]

  • 16. Review staff at FDA.
    Goldhammer A.
    Science; 1997 May 02; 276(5313):661. PubMed ID: 9157539
    [No Abstract] [Full Text] [Related]

  • 17. Trump to nominate Scott Gottlieb as FDA commissioner despite industry links.
    Lenzer J.
    BMJ; 2017 Mar 15; 356():j1339. PubMed ID: 28298314
    [No Abstract] [Full Text] [Related]

  • 18. US FDA feels the heat from Congressional hearings.
    Loewenberg S.
    Lancet; 2008 May 10; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract] [Full Text] [Related]

  • 19. New leadership for the FDA.
    Lancet; 2002 Oct 19; 360(9341):1183. PubMed ID: 12401238
    [No Abstract] [Full Text] [Related]

  • 20. New "21st Century Cures" Legislation: Speed and Ease vs Science.
    Kesselheim AS, Avorn J.
    JAMA; 2017 Feb 14; 317(6):581-582. PubMed ID: 28056124
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.